Article short contents

Slovenska pediatrija 2026; 33: 248-254

https://doi.org/10.38031/slovpediatr-2026-4-07en

: 2
- Show Article PDF
- Download Article PDF
Review article

PITFALLS IN THE MEDICINE CABINET: THE PHARMACIST’S ROLE IN THE TREATMENT OF CHILDREN WITH CHRONIC KIDNEY DISEASE AND RARE DISEASES WITH KIDNEY INVOLVEMENT

Tomislav Laptoš
Univerzitetni klinični center, Ljubljana, Slovenija

Matjaž Kopač
Klinični oddelek za nefrologijo, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Slovenija in Katedra za pediatrijo, Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenija

Tanja Kersnik Levart
Klinični oddelek za nefrologijo, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Slovenija in Katedra za pediatrijo, Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenija

Abstract

Children with chronic kidney disease (CKD) and rare diseases with kidney involvement form a small but therapeutically demanding group of patients, in whom treatment success is closely linked to the feasibility of therapy at home, at school and at mealtimes. Many supportive medicines are not available in authorized formulations and strengths suitable for children, so extemporaneous preparation is often required, and for some medicines it is available only in a hospital pharmacy. Further challenges include supply disruptions, reimbursement listing by the Health Insurance Institute of Slovenia, and medication reconciliation at transitions between disease stages and levels of care. To ensure safe medication administration in different settings, preparing and regularly updating a Personal medication card is important. In the specific treatment of rare diseases with kidney involvement, such as complement inhibitors, siRNA-based medicines and cysteamine, high prices and a difficult journey to the Slovenian market are accompanied by important safety warnings, e.g., vaccination before initiating complement inhibitors. Integrating the pharmacist into the multidisciplinary team significantly contributes to preventing errors, improving adherence, and supporting the gradual transition of adolescents to self-management of their therapy.

Key words: Chronic kidney disease; child; pharmaceutical services; drug compounding; adherence; complement inactivating agents; rare diseases